Last. Sofia Rivera(University of Paris-Sud)H-Index: 13
view all 9 authors...
Due to the continuously increasing number of newly diagnosed breast cancer and limited health resources hypofractionated radiotherapy is a major topic. Recent results from randomized clinical trials assessing extreme hypofractionated radiotherapy for whole or partial breast radiotherapy are practice changing. Here we report toxicity and oncological outcomes from major recent trials of extreme hypofractionated breast irradiation and present an ongoing prospective implementation program. For whole...
Abstract null null Management of high-risk prostate cancers is still a subject of debate, because of the lack of randomized trial comparing surgery and radiotherapy. If external beam radiotherapy is proposed, it must be associated with a long-term androgen deprivation therapy, at least 18-months. Irradiation of pelvic lymph nodes seems to improve distant metastasis-free survival and is so indicated in most of the cases. Moderate hypofractionation is not validated for pelvic lymph nodes irradiati...
In the management of prostate cancer in recent years, innovative therapies have appeared requiring precise and reliable disease detection. In 2021, new generation imaging (PET/CT, multiparametric MRI, PET/MRI) have their place at all stages of the prostate cancer natural history to help target the lesion(s) and guide therapy and improve the results obtained. PSMA PET/CT is currently the leader in this type of imaging with a complete offer during the disease: both from diagnosis, to recurrence or...
Abstract null null Approximately thirty percent of patients experience biochemical recurrence after radical prostatectomy for prostate cancer. Early salvage radiotherapy has recently become a standard of care in this setting. The purpose of this review is first to summarize current knowledge in terms of dose to the prostate bed in light of the recent SAKK 09/10 randomized phase III trial results. The evidence on moderate hypofractionation will also be discussed whereas extreme hypofractionation ...
Last. David Pasquier(Lille University of Science and Technology)H-Index: 22
view all 9 authors...
Resume null null Le cancer de la prostate oligometastatique est parmi les cancers oligometastatiques les plus etudies dans la litterature. Malgre cela, a ce jour, nous disposons de peu d’etudes prospectives ayant evalue la radiotherapie stereotaxique des oligometastases du cancer de la prostate. Deux essais randomises de phase II montrent un benefice en termes de survie sans progression en comparaison avec une surveillance simple. Les donnees de registres prospectifs montrent egalement un tres b...
In 2021, the Ethics Commission of the SFRO has chosen the issue of the practice of palliative care in radiotherapy oncology. Radiation oncology plays a central role in the care of patients with cancer in palliative phase. But behind the broad name of palliative radiotherapy, we actually find a large variety of situations involving diverse ethical issues. Radiation oncologists have the delicate task to take into account multiple factors throughout a complex decision-making process. While the ques...
Resume null null Les carcinomes basocellulaires et les carcinomes epidermoides cutanes sont parmi les tumeurs cancereuses les plus frequentes dans le monde. Leur traitement repose le plus souvent sur leur exerese chirurgicale. Une radiotherapie adjuvante peut etre indiquee en cas de facteur de risque de recidive ou bien en alternative a la chirurgie si celle-ci n’est pas realisable du fait du grand âge des patients, de leur comorbidite ou en alternative a une chirurgie potentiellement mutilante....
Last. Eric Deutsch(Université Paris-Saclay)H-Index: 58
view all 4 authors...
Numerous clinical studies aim to integrate immunotherapy in radiotherapy oncology, either for generating abscopal responses in metastatic patients in combination with radiotherapy, or in the treatment of a locally advanced tumor. The search for biomarkers of response to treatment is a major axis in the development of these therapeutic combinations, to allow the early identification of patients who will benefit from the treatment, in the context of an increasingly personalized approach. We review...
Resume null null Objectif de l’etude null La prostatectomie totale est un standard de traitement pour les patients atteints d’un cancer de prostate localise non metastatique. Pres de 30 % des patients operes, verront se developper une rechute biochimique dans les dix annees suivant la prostatectomie totale. De plus, 30 % des cancers traites chirurgicalement presenteront des caracteristiques pathologiques agressives majorant ce risque de rechute biochimique. null null null Materiel et Methodes nu...
Numerous clinical studies aim to integrate immunotherapy in radiotherapy oncology, either for generating abscopal responses in metastatic patients in combination with radiotherapy, or in the treatment of a locally advanced tumor. The search for biomarkers of response to treatment is a major axis in the development of these therapeutic combinations, to allow the early identification of patients who will benefit from the treatment, in the context of an increasingly personalized approach. We review...